What Has Been the Progress and Growth of the Pediatric Vaccine Market in Recent Years?
The pediatric vaccine market has seen considerable growth due to a variety of factors.
• In the past few years, there has been a fast-paced growth in the pediatric vaccine market size. The market is expected to expand from $45.9 billion in 2024 to $51.56 billion in 2025, marking a compound annual growth rate (CAGR) of 12.3%.
The development in the historical period is largely due to the rise in chronic diseases, introduction of immunization policies to eliminate endemic diseases, and improved funding for the development of vaccines.
What Can Be Expected from the Pediatric Vaccine Market in the Coming Years?
The pediatric vaccine market is expected to maintain its strong growth trajectory in upcoming years.
• Over the coming years, the pediatric vaccine market is set to experience a substantial surge, expanding to $85.3 billion in 2029, with a compound annual growth rate (CAGR) of 13.4%.
This development in the predicted timeframe is due to factors like the rising incidents of invasive cervical cancer, a robust late-stage pipeline, and new drug approvals as well as the growing presence of infectious diseases. Noteworthy trends for this period involve the creation of combination vaccines to fulfill market requirements, allocating funds for research and development to create effective vaccines, concentrating on the production of live attenuated vaccines, employing cutting-edge immune engineering and advanced delivery systems, and integrating artificial intelligence (AI) into vaccine development to streamline the process and facilitate easy production.
Which Factors Are Boosting Growth In The Pediatric Vaccine Market?
The escalating incidence of chronic ailments like tuberculosis, diphtheria, and pneumonia in children aged 15 years and below is expected to propel the expansion of the pediatric vaccines market. The probability of severe outcomes and complications from infectious diseases is rising among children and teenagers with chronic conditions. The Australian Bureau of Statistics, an autonomous statutory body in Australia responsible for data gathering and interpretation, stated in March 2022 that nearly half of the total population (46.6%, approximately 11.6 million people) suffered from a minimum of one chronic illness. This heightened presence of chronic conditions in children stimulates the need for immunization against these diseases, thereby fueling the growth of the pediatric vaccine market.
How Are The Segments Defined Within The Global Pediatric Vaccine Market?
The pediatric vaccine market covered in this report is segmented –
1) By Vaccine Type: Monovalent, Multivalent
2) By Technology: Live Attenuated, Inactivated, Toxoid, Conjugate, Other Technologies
3) By Application: Infectious Disease, Allergy, Cancer
Subsegments:
1) By Monovalent: Single Antigen Vaccines, Specific Disease Vaccines
2) By Multivalent: Combination Vaccines, Polyvalent Vaccines
Pre-Book The Pediatric Vaccine Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
How Are New Trends Expected To Influence The Growth Of The Pediatric Vaccine Market?
The growing need for innovative vaccines aimed at providing enhanced protection against difficult-to-treat infectious diseases like tuberculosis, HIV/AIDS, as well as non-communicable chronic diseases like cancer and neurodegenerative diseases, is evident. New methodologies in vaccine creation, such as the design of structural immunogenic, gene-based vaccine platforms, and potent adjuvant recombinant antigen formulations, are being utilised. This necessitates an ongoing pursuit by paediatric vaccine makers and developers to introduce innovative approaches to vaccine design and manufacturing technology. For example, in April 2023, Pfizer Inc., an American pharmaceutical manufacturing firm, announced the approval of REVNAR 20, a 20-valent Pneumococcal Conjugate Vaccine for infants and children, by the U.S. FDA.
Who Are the Key Players in the Pediatric Vaccine Market?
Major companies operating in the pediatric vaccine market include:
• Merck & Co. Inc.
• Serum Institute of India Pvt. Ltd.
• Sanofi SA
• Pfizer Inc.
• AstraZeneca
• GlaxoSmithKline PLC
• Sinovac Biotech Ltd
• Zydus Cadila
• Indian Immunologicals Limited
• Panacea Biotec
• Takeda Pharmaceutical Company
• Mitsubishi Tanabe Pharma Corporation
• Daiichi Sankyo
• CSL Limited
• BIO-MED
• Sun Pharmaceutical Industries Ltd
• Sinopharm
• Walvax biotechnology
• Fosun Pharma
• BioNTech
• MCM Vaccine Company
• Seqirus
• Roche
• Johnson & Johnson
• Novartis
• Connaught LaboratoriesInc.
• Wyeth-Ayerst
• Grifols
• Ataulfo de Paiva Foundation
• Bio-Manguinhos–Institute of Technology on Immunobiologicals
• Butantan Institute
• Ezequiel Dias Foundation (FUNED)
• Sinergium
What Is The Most Dominant Region In The Pediatric Vaccine Market?
North America was the largest region in the pediatric vaccine market in 2024. Middle East is expected to be the largest growing region in the global pediatric vaccine market share during the forecast period. The regions covered in the pediatric vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
